-
-
-
-
-
-
-
Merck to present oncology data across 25 cancer types at ASCO 2026
-
-
-
-
-
-
-
Merck beats quarterly sales expectations as Keytruda fuels growth
-
-
-
-
-
-
-
Truist Securities Downgrades Terns Pharmaceuticals (TERN) to Hold
-
-
-
-
-
-
-
Barclays on Merck (MRK): Terns deal shows Merck shifting toward 'more diversified onco strategy'
-
-
-
-
-
-
-
Merck presents cancer treatment data at ASCO GU symposium
-
-
-
-
-
-
-
Merck (MRK) PT Raised to $124 at Leerink Partners
-
-
-
-
-
-
-
Merck bets on flu prevention with $9.2 billion deal for Cidara Therapeutics
-
1,157,996 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

